Milton Waner
Research Subjects
Milton Waner has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Teresa Minjung O
Vascular Birthmark Institute of New York, New York, New York, USA
3 shared publications Teresa M. O
Department of Otolaryngology-Head and Neck Surgery, Vascular Birthmark Institute of New York, Facial Nerve Center, Manhattan Eye, Ear and Throat Hospital, 210 East 64th Street, 7 Floor, New York, NY 10065, USA
2 shared publications- Aaron Fay
Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts
1 shared publication - Karin Petra Quirina Oomen
Clinica Omega Zeta
1 shared publication - Stefan Waner
Hofstra University
1 shared publication Tara E. Brennan
Vascular Birthmark Institute of New York, New York2Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, University of New Mexico, Albuquerque3Department of Otolaryngology, Manhattan Eye, Ear and Throat Hospitals, New York, New York4Department of Otolaryngology, Lenox Hill Hospital, New York, New York
1 shared publication
Latest Publications
- Open Access
- 16 December 2025
- Published by Springer Nature in Research Square
Intranasal bleomycin versus Avastin® sclerotherapy as an adjunct to laser treatment for epistaxis in hereditary hemorrhagic telangiectasia
Background Hereditary hemorrhagic telangiectasia is a rare disease of vascular development, often accompanied by severe epistaxis. Multimodality treatment may improve epistaxis control, but the optimal combination of modalities has not yet been established. Objective To compare the effects of adding intranasal bleomycin versus Avastin® sclerotherapy to laser treatment for epistaxis in patients with hereditary hemorrhagic telangiectasia. Methods We retrospectively studied the medical records of all hereditary hemorrhagic telangiectasia patients who underwent laser therapy with or without bleomycin or Avastin® sclerotherapy for epistaxis during eight consecutive years. We calculated the mean posttreatment epistaxis severity score changes, proportions of procedures after which a minimal important difference in epistaxis severity score was reached, and intervals between subsequent treatments. Results The mean epistaxis severity score change was significantly higher after laser combined with bleomycin, compared to laser treatment alone. The mean treatment interval after both laser combined with Avastin®, and laser combined with bleomycin, were significantly longer compared to laser treatment alone. Conclusions Adding bleomycin to laser treatment may lead to greater epistaxis severity score improvement compared to laser treatment only or laser combined with Avastin® in patients with hereditary hemorrhagic telangiectasia. Adding bleomycin or Avastin® to laser seems to lengthen treatment intervals compared to laser therapy alone.
- 16 December 2025
- Published by Springer Nature in Research Square
Open AccessIntranasal bleomycin versus Avastin® sclerotherapy as an adjunct to laser treatment for epistaxis in hereditary hemorrhagic telangiectasia
Background Hereditary hemorrhagic telangiectasia is a rare disease of vascular development, often accompanied by severe epistaxis. Multimodality treatment may improve epistaxis control, but the optimal combination of modalities has not yet been established. Objective To compare the effects of adding intranasal bleomycin versus Avastin® sclerotherapy to laser treatment for epistaxis in patients with hereditary hemorrhagic telangiectasia. Methods We retrospectively studied the medical records of all hereditary hemorrhagic telangiectasia patients who underwent laser therapy with or without bleomycin or Avastin® sclerotherapy for epistaxis during eight consecutive years. We calculated the mean posttreatment epistaxis severity score changes, proportions of procedures after which a minimal important difference in epistaxis severity score was reached, and intervals between subsequent treatments. Results The mean epistaxis severity score change was significantly higher after laser combined with bleomycin, compared to laser treatment alone. The mean treatment interval after both laser combined with Avastin®, and laser combined with bleomycin, were significantly longer compared to laser treatment alone. Conclusions Adding bleomycin to laser treatment may lead to greater epistaxis severity score improvement compared to laser treatment only or laser combined with Avastin® in patients with hereditary hemorrhagic telangiectasia. Adding bleomycin or Avastin® to laser seems to lengthen treatment intervals compared to laser therapy alone.
- 1 February 2018
- Published by Elsevier in Otolaryngologic Clinics of North America
- Vol. 51 (1) , 125-131
The Surgical Management of Infantile Hemangiomas
- 1 February 2018
- Published by Elsevier in Otolaryngologic Clinics of North America
- Vol. 51 (1) , 125-131
The Surgical Management of Infantile Hemangiomas
- 1 February 2018
- Published by Elsevier in Otolaryngologic Clinics of North America
- Vol. 51 (1) , 159-172
Multidisciplinary Approach to the Management of Lymphatic Malformations of the Head and Neck
- 1 February 2018
- Published by Elsevier in Otolaryngologic Clinics of North America
- Vol. 51 (1) , 159-172
Multidisciplinary Approach to the Management of Lymphatic Malformations of the Head and Neck
- 1 February 2018
- Published by Elsevier in Otolaryngologic Clinics of North America
- Vol. 51 (1) , XVII-XVIII
Congenital Vascular Lesions of the Head and Neck
- 1 February 2018
- Published by Elsevier in Otolaryngologic Clinics of North America
- Vol. 51 (1) , XVII-XVIII
Congenital Vascular Lesions of the Head and Neck
- Open Access
- 1 July 2017
- Published by SAGE Publications in JAMA Facial Plastic Surgery
- Vol. 19 (4) , 282-286
The Tissue Expander Effect in Early Surgical Management of Select Focal Infantile Hemangiomas
Infantile hemangiomas (IHs) are the most common tumors of infancy. Girls are more commonly affected than boys, and 65% of IHs involve the head and neck.1,2 Infantile hemangiomas are also more common among fair-skinned infants. Facial IHs have been noted to occur more commonly at regions of embryologic fusion.3 Infantile hemangiomas may be focal or segmental, the latter of which may be associated with PHACES (posterior fossa brain malformations, hemangiomas [large segmental], arterial anomalies, cardiac/heart anomalies, ear/eye/endocrine abnormalities, sternal cleft/supraumbilical raphe) syndrome. Airway lesions may also be found in either a focal or segmental distribution and are particularly associated with V3 segmental IHs.
- 1 July 2017
- Published by SAGE Publications in JAMA Facial Plastic Surgery
- Vol. 19 (4) , 282-286
Open AccessThe Tissue Expander Effect in Early Surgical Management of Select Focal Infantile Hemangiomas
Infantile hemangiomas (IHs) are the most common tumors of infancy. Girls are more commonly affected than boys, and 65% of IHs involve the head and neck.1,2 Infantile hemangiomas are also more common among fair-skinned infants. Facial IHs have been noted to occur more commonly at regions of embryologic fusion.3 Infantile hemangiomas may be focal or segmental, the latter of which may be associated with PHACES (posterior fossa brain malformations, hemangiomas [large segmental], arterial anomalies, cardiac/heart anomalies, ear/eye/endocrine abnormalities, sternal cleft/supraumbilical raphe) syndrome. Airway lesions may also be found in either a focal or segmental distribution and are particularly associated with V3 segmental IHs.
- 1 January 2015
- Published by Springer Nature
- p. 357-367
Vascular Malformations of the Orbit
- 1 January 2015
- Published by Springer Nature
- p. 343-355
Upper Airway Congenital Vascular Lesions
- 1 January 2015
- Published by Springer Nature
- p. 137-144
Treatment of Infantile Hemangiomas of the Head and Neck
- 1 January 2015
- Published by Springer Nature
- p. 137-144
Treatment of Infantile Hemangiomas of the Head and Neck